First patient dosed in the UK with a new lung cancer vaccine – Oncogene Cancer Research
Oncogene Cancer Research shared a post on LinkedIn:
“Big news out today in the UK: first patient dosed in the UK with a new lung cancer vaccine. The vaccine is aimed in combination with other immunotherapy agents and for those with unresectable NSCLC after chemoradiotherapy. The trial is running across seven countries – including the US, Germany, Hungary, Poland, Spain and Turkey.
‘It is the first time this immunotherapy made by BioNTech, the German biotechnology company, will be studied in a clinical trial for lung cancer in the UK, where the NIHR UCLH Clinical Research Facility is the lead research site.’
‘The investigational mRNA cancer immunotherapy for non-small cell lung cancer (NSCLC) – known as BNT 116 – utilises a messenger RNA (mRNA) to present common tumour markers from NSCLC to the patient’s immune system, with the aim of helping the immune system recognise and fight cancer cells expressing these markers’.
Fantastic to see more research in ways to better treat and cure all lung cancers.